3-氨基-1,1,1-三氟丙烷-2-醇 | 431-38-9

• 物质功能分类: 有机原料 - 有机氟化合物 - 氟丙烷系列
• 分子结构分类: 有机化合物 - 有机卤素化合物 - 卤代醇
• 中文名称: 3-氨基-1,1,1-三氟丙烷-2-醇
• 中文别名: 3-氨基-1,1,1-三氟-2-丙醇
• 英文名称: 3-amino-1,1,1-trifluoropropan-2-ol
• 英文别名: 3-amino-1,1,1-trifluoro-2-propanol；2-amino-1-trifluoromethylethanol；2-hydroxy-2-(trifluoromethyl)ethylamine
• CAS: 431-38-9
• 化学式: C₃H₆F₃NO
• mdl: MFCD02082679
• 分子量: 129.082
• InChiKey: RISHBQWFBUTROQ-UHFFFAOYSA-N

物化性质

• 熔点：
  99°C
• 沸点：
  176.5±40.0 °C(Predicted)
• 密度：
  1.344±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于DMSO（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  46.2
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S36/37/39,S39
• 危险类别码：
  R34
• 危险品运输编号：
  UN 3259
• 海关编码：
  2922199090
• 危险性防范说明：
  P280,P305+P351+P338,P310
• 危险性描述：
  H302,H315,H319,H332,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
3-Amino-1,1,1-trifluoropropan-2-ol
Product Name:
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H318: Causes serious eye damage
H335: May cause respiratory irritation
H412: Harmful to aquatic life with long lasting effects
Avoid breathing dust/fume/gas/mist/vapours/spray
P261:
P273: Avoid release to the environment
P280: Wear protective gloves/protective clothing/eye protection/face protection
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing

---

Section 3. Composition/information on ingredients.
3-Amino-1,1,1-trifluoropropan-2-ol
Ingredient name:
CAS number: 431-38-9

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C3H6F3NO
Molecular weight: 129.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-氨基-1,1,1-三氟丙烷-2-醇 在 silica gel 作用下， 以 环己烷 、 苯 为溶剂， 生成 (2S)-3-氨基-1,1,1-三氟-2-丙醇
  参考文献：
  名称：

  通过非手性色谱通过对映体自歧化进行光学纯化：一系列含α-CF3的仲醇的案例研究

  摘要：

  这项工作表明，可以推荐通过非手性色谱法对映体自歧化，作为廉价且通用的光学纯化对映体富集化合物的常规方法。特别是，这种方法相对于常规重结晶的优势在于，它既可以用于结晶化合物，也可以用于液体化合物。手征性，25：365-368，2013。©2013 Wiley Periodicals，Inc.

  DOI：

  10.1002/chir.22180
• 作为产物：
  描述：

  (5Z,8Z,11Z,14Z)-N-(3,3,3-trifluoro-2-hydroxypropyl)icosa-5,8,11,14-tetraenamide 在 maltose-binding protein-recombinant fatty acid amide hydrolase 作用下， 以 aq. phosphate buffer 、 重水 为溶剂， 生成 3-氨基-1,1,1-三氟丙烷-2-醇
  参考文献：
  名称：

  基于片段的n-FABS NMR筛选应用于膜酶FAAH的开发

  摘要：

  片段的氟：我们证明了基于19 F NMR片段的生化筛选（n -FABS）在膜蛋白脂肪酸酰胺水解酶（FAAH）上的首次应用。通过这种方法鉴定出的片段命中具有对FAAH的微摩尔抑制值，显示了该方法在其他膜蛋白应用中的潜力。S：底物，P：产品。

  DOI：

  10.1002/cbic.201300347

文献信息

• [EN] 2-HETEROARYL-3-OXO-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES FOR THE TREATMENT OF CANCER<br/>[FR] 2-HÉTÉROARYL-3-OXO-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES POUR LE TRAITEMENT DU CANCER
  申请人：BAYER AG

  公开号：WO2018146010A1

  公开（公告）日：2018-08-16

  The present invention covers 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamide compounds of general formula (I), in which X, R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer or conditions with dysregulated immune responses or other disorders associated with aberrant AHR signaling, as a sole agent or in combination with other active ingredients.

  本发明涵盖了一般式(I)的2-杂环芳基-3-酮基-2,3-二氢吡啶嗪-4-羧酰胺化合物，其中X、R1、R2、R3、R4和R5如本文所定义，制备所述化合物的方法，用于制备所述化合物的有用中间体化合物，包含所述化合物的药物组合物和组合物，以及利用所述化合物制造用于治疗或预防疾病的药物组合物，特别是癌症或与异常AHR信号传导相关的疾病，或与失调免疫反应或其他与异常AHR信号传导相关的疾病，作为单一药剂或与其他活性成分组合使用。
• [EN] SULPHAMOYLARYL DERIVATIVES AND USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF LIVER FIBROSIS<br/>[FR] DÉRIVÉS DE SULPHAMOYLARYLE ET LEUR UTILISATION EN TANT QUE MÉDICAMENTS POUR LE TRAITEMENT DE LA FIBROSE HÉPATIQUE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2018145620A1

  公开（公告）日：2018-08-16

  Potent 5-HT2B antagonist of Formula (A), including stereochemically isomeric forms, and salts, hydrates, solvates thereof and their use wherein R1 to R4 and Ar have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them, alone or in combination with other drugs, in fibrosis and/or cirrhosis prevention or therapy.

  强效的Formula（A）的5-HT2B拮抗剂，包括立体化异构形式，以及其盐、水合物、溶剂合物及其用途，其中R1至R4和Ar的含义如本文所定义。本发明还涉及制备所述化合物的方法，含有它们的药物组合物，单独或与其他药物联合在纤维化和/或肝硬化预防或治疗中的用途。
• [EN] BICYCLIC JAK INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE JAK BICYCLIQUES ET LEURS UTILISATIONS
  申请人：INSILICO MEDICINE IP LTD

  公开号：WO2020198583A1

  公开（公告）日：2020-10-01

  Provided herein are compounds of Formulas (I), (II), (III), and (IV) and subformulas thereof, wherein the variables are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I), (II), (III), or (IV) and methods of using the compounds, e.g., in the treatment of immune disorders, inflammatory disorders, and cancer.

  本文提供了公式（I）、（II）、（III）和（IV）及其子公式的化合物，其中变量在此处定义。本文还提供了包括公式（I）、（II）、（III）或（IV）化合物的药物组合物，以及使用这些化合物的方法，例如用于治疗免疫紊乱、炎症性疾病和癌症。
• The synthesis of fluorine-containing pterins
  作者：Caroline Dunn、Colin L. Gibson、Colin J. Suckling

  DOI：10.1016/0040-4020(96)00782-x

  日期：1996.9

  The synthesis of some 7,7-difluoro-7,8-dihydropterins and pterins with fluoroalkyl subsitutents at the 6 or 7 positions from fluorine-containing aliphatic precursors and suitably substituted pyrimidines is described. The fluorine-containing pterins were found to be very insoluble and also stable to nucleophiles and bases in dilute aqueous solution.

  描述了一些7,7-二氟-7,8-二蝶呤和蝶呤从含氟的脂肪族前体和适当取代的嘧啶的6或7位上带有氟烷基取代基的合成。发现含氟的蝶呤非常不溶，并且对稀水溶液中的亲核试剂和碱也稳定。
• [EN] PHENYL-3-AZA-BICYCLO[3.1.0]HEX-3-YL-METHANONES AND THE USE THEREOF AS MEDICAMENT<br/>[FR] PHÉNYL-3-AZA-BICYCLO[3.1.0]HEX-3-YL-MÉTHANONES ET LEUR UTILISATION EN TANT QUE MÉDICAMENT
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2013017657A1

  公开（公告）日：2013-02-07

  The present inventions relates to substituted phenyl-3-aza-bicyclo[3.1.0]hex-3-yl- methanones of general formula (I) wherein R1, R2, R3, R4, R5 and R6 are as herein described or salts thereof, preferably pharmaceutically acceptable salts thereof. The invention further relates to the manufacture of said compounds, pharmaceutical compositions comprising a compound according to general formula (I), and the use of said compounds for the treatment of various conditions such as conditions concerning positive and negative symptoms of schizophrenia as well as cognitive impairments associated with schizophrenia, Alzheimers Disease and other neurological and psychiatric disorders. The compounds of the invention show glycine transporter-1 (GlyT1) inhibiting properties.

  本发明涉及通式（I）所示的取代苯基-3-氮杂双环[3.1.0]己-3-基甲酮，其中R1、R2、R3、R4、R5和R6如本文所述或其盐，优选为其药学上可接受的盐。本发明还涉及所述化合物的制备，包含符合通式（I）的化合物的药物组合物，以及利用所述化合物治疗各种疾病的用途，如涉及精神分裂症的阳性和阴性症状以及与精神分裂症、阿尔茨海默病和其他神经和精神障碍相关的认知障碍。本发明的化合物显示甘氨酸转运蛋白-1（GlyT1）抑制性能。

表征谱图